Related content

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer

By          

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 721-727

Spandidos Publications

Access to resources Recommend Favorite

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

By Kao Hsiang-Fong   Lin Chia-Chi   Yang James Chih-Hsin  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 991-1003

Future Medicine

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer - a phase II trial

By Laack E.   Mende T.   Benk J.   Chemaissani A.   Scholtze J.   Lorenz C.   Niestroy A.   Dalhoff K.   Muller T.   Walter T.   Durk H.   Edler L.   Hossfeld D.K.  

European Journal of Cancer, Vol. 37, Iss. 5, 2001-03 ,pp. : 583-590

Elsevier

Access to resources Recommend Favorite